CARsgen Therapeutics Holdings Limited e' una societa' quotata del settore Healthcare, HKG, con codice di borsa 2171 su SEHK.
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma. It is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma, relapsed/refractory primary plasma cell leukemia, relapsed/refractory plasma cell leukemia, and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT0596, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R MM, PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence; KJ-C2527, which is in the pre-clinical stage to treat gastric cancer; CT1390B, which is in the pre-clinical stage to treat AML; and KJ-C2529, which is in the pre-clinical stage to treat B-cell malignancies. Additionally, it engages in drug research and development, manufacture and import and export handling business. The company was founded in 2014 and is headquartered in Shanghai, China.
ForwardAlpha calcola per CARsgen Therapeutics Holdings Limited un Value Score, un Growth Score e un Best Score proprietari, ottenuti confrontando la societa' con tutte le altre del suo mercato su valutazione, crescita degli utili e dei ricavi e andamento del prezzo. I punteggi sono riservati agli utenti registrati: l'iscrizione e' gratuita.
Grafico dei prezzi a cinque anni, rendimenti a una settimana, un mese, sei mesi, dodici mesi, tre e cinque anni, multipli di valutazione, confronto con la media del settore e posizionamento nel proprio mercato di quotazione.
Stock not found: 2171.SEHK